Abstracts tagged "Polymyositis/dermatomyositis (PM/DM)"

Abstract Number: 398 • 2019 ACR/ARP Annual Meeting
Seasonal Variation in Idiopathic Inflammatory Myopathies Incidence and Presentation: A Retrospective Study in Beijing and Hong Kong
Ho SO ¹, Yawen SHEN², Victor Tak Lung WONG ¹, Roy HO ¹ and Xin LU ², ¹Kwong Wah Hospital, Kowloon, Hong Kong, ²China Japan Friendship Hospital, BeiJing, China (People's Republic)
Background/Purpose: Seasonal patterns of disease onset and severity in idiopathic inflammatory myopathies (IIMs) as a whole are conflicting. In recent years, over 10 myositis-specific antibodies…
Abstract Number: 407 • 2019 ACR/ARP Annual Meeting
Utility of Anti-SSA/SSB Assay and Anti-Ro 52 Antibody Assay in Routine Clinical Practice for Risk Assessment of Patients with Idiopathic Inflammatory Myositis
Galina Marder ¹, Sonali Narain², Maria-Louise Barilla-Labarca ¹ and Ana Valle ¹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, ²Northwell Health, Great Neck, Long Island, NY
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic autoimmune diseases affecting multiple organ systems and associated with a diverse autoantibody profile. Anti-SSA/SSB are the most frequent…
Abstract Number: 1275 • 2019 ACR/ARP Annual Meeting
Spectrum of Organ Involvement in Idiopathic Inflammatory Myopathies, Frequency of Comorbidities, and Relationship to Anti-SSA/SSB Positivity
Ana Valle¹, Galina Marder ¹, Maria-Louise Barilla-Labarca ¹ and Sonali Narain ², ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, ²Northwell Health, Great Neck, Long Island, NY
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic autoimmune diseases with systemic features and multiple comorbidities. Of the myositis associated antibodies seen in this population, anti-SSA/SSB…
Abstract Number: 1293 • 2019 ACR/ARP Annual Meeting
Multiple Subpopulations of Lymphocytes Were Absolutely Decreased in Dermatomyositis/polymyositis Patients and Restored by Low-dose IL-2
Jia Wang ¹, He-hua Sun ¹, Sheng-xiao Zhang², Jia-qian Zhang ¹, Jiang Bai ³, Jing Luo ³, Cai-hong Wang ⁴, Chong Gao ⁵ and Xiao-feng Li ¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ²The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China (People's Republic), ³Shanxi Medical University, Taiyuan, China (People's Republic), ⁴The Second Hospital of Shanxi Medical University, Tai Yuan, China (People's Republic), ⁵Brigham and Women’s Hospital, Harvard Medical School, Boston
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare chronicinflammatory disorders with significant associated morbidityand mortality despite treatment, characterized by subacute onset of proximal muscle weakness,…
Abstract Number: 1870 • 2019 ACR/ARP Annual Meeting
NMR-Based Serum, Urine and Muscle Metabolomics in Inflammatory Myositis for Diagnosis and Activity Assessment: Serum Metabolomics Can Differentiate Active from Inactive Myositis
Latika Gupta¹, Dinesh Kumar ², Umesh Kumar ³, Anupam Guleria ², Abhishek Zanwar ⁴, Ritu Raj ⁵ and Ramnath Misra ¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ²Centre for Biomedical Research, Sanjay Gandhi Post Graduate Institute of Medical Science, Lucknow, Uttar Pradesh, India, ³Centre of Biomedical Research SGPGIMS, Raibareli Road, Lucknow-226014, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁵Centre of Biomedical Research, Lucknow, Uttar Pradesh, India
Background/Purpose: Differentiating smouldering disease activity from weakness due to fatty replacement of atrophied muscle can often be a challenge in Idiopathic Inflammatory Myositis (IIM). There…
Abstract Number: 397 • 2019 ACR/ARP Annual Meeting
Clinical Features of Polymyositis and Dermatomyositis Patients with Severe Dysphagia
Nozomi Takasugi¹, Yutaro Hayashi ¹, Keisuke Izumi ², Satoshi Hama ³, Misako Konishi ¹, Mari Ushikubo ¹, Yutaka Okano ¹ and Hisaji Ohshima ¹, ¹National Tokyo Medical Center, tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³tokyo medical center, tokyo, Japan
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are autoimmune inflammatory diseases characterized by proximal myositis. Dysphagia has been reported to develop in 35 to 62% of…
Abstract Number: 1210 • 2018 ACR/ARHP Annual Meeting
Sonographic Appearance of Inflammatory Myopathies: Increased Muscle Echointensity and Qualitative Changes
Kristofoor Leeuwenberg¹, Lisa Christopher-Stine¹, Clifton O. Bingham III², Julie J. Paik², Eleni Tiniakou³, Seth Billings⁴, Philippe Burlina⁴ and Jemima Albayda⁵, ¹Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University Applied Physics Lab, Laurel, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The use of ultrasound in the assessment of muscle conditions has grown over the years. Various myopathies have shown an increase in echo intensity…
Abstract Number: 277 • 2016 ACR/ARHP Annual Meeting
Abnormal Composition of Circulating T and B Cells in Patients with Polymyositis and Dermatomyositis Is More Biased in Those with Interstitial Lung Diseases
Hirokazu Sasaki, Akito Takamura, Kimito Kawahata and Hitoshi Kohsaka, Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are systemic inflammatory myopathies. They sometimes accompany interstitial lung disease (ILD), which can lead often to fatal outcome. For…
Abstract Number: 288 • 2015 ACR/ARHP Annual Meeting
Myositis Associated Interstitial Lung Disease: Clinical Predictors of Failure to Conventional Treatment and Their Response to Tacrolimus
Niharika Sharma¹, Anisha Dua¹, Michael Putman², Rekha Vij³ and Mary Strek³, ¹Rheumatology, The University of Chicago, Chicago, IL, ²Internal Medicine, The University of Chicago, Chicago, IL, ³Pulmonology, The University of Chicago, Chicago, IL
Background/Purpose: Interstitial lung disease (ILD) frequently complicates Polymyositis (PM) and Dermatomyositis (DM) and accounts for significant morbidity and mortality in affected patients. Patients with Myositis…
Abstract Number: 948 • 2015 ACR/ARHP Annual Meeting
Autoimmune Myopathies: Effects of Intravenous Immunoglobulin Therapy on Muscle Strength and Predictors of Response
Arash Lahoutiharahdashti¹, Iago Pinal-Fernandez², Jemima Albayda¹, Julie J. Paik³, Sonye K. Danoff⁴, Andrew Mammen⁵ and Lisa Christopher-Stine⁶, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Autoimmune Systemic Diseases Unit, Vall D’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, ⁵Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Ste 4100 Rm 409, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: There is a variable response rate to Intravenous immunoglobulin (IVIG) in patients with autoimmune myopathies. The aim of this study was to determine whether…
Abstract Number: 2222 • 2014 ACR/ARHP Annual Meeting
Predictors of Myositis Treatments Received and Associated Treatment Responses in Myovision, a National Myositis Patient Registry
Abdullah Faiq¹, Payam Noroozi Farhadi¹, Jesse Wilkerson², Nastaran Bayat¹, Anna Jansen³, Kathryn Rose⁴, Lukasz Itert⁵, Anne Johnson⁶, Christine Parks⁷, Edward H. Giannini⁸, Hermine I. Brunner⁹, Bob Goldberg¹⁰, Richard Morris⁴, Frederick W. Miller¹ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Social and Scientific Systems, Inc., Research Triangle Park, NC, ³Environmental Autoimmunity Group, NIEHS / EAG, Bethesda, MD, ⁴Social and Scientific Systems, Inc., Durham, NC, ⁵Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Epidemiology Branch, NIEHS, NIH, Research Triangle Park, NC, ⁸Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹PRCSG, Cincinnati, OH, ¹⁰The Myositis Association, Alexandria, VA
Background/Purpose: Little is known about medications received for myositis and patients’ responses to therapies. We present information on self-reported myositis therapy use and responses from…
Abstract Number: 1261 • 2014 ACR/ARHP Annual Meeting
Pulmonary Arterial Hypertension in Patients with Anti-PM-Scl Antibody
Hiromichi Tamaki¹, Colin O'Rourke² and Soumya Chatterjee³, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ³Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH
Background/Purpose: Patients with anti-PM-Scl antibody (PM-Scl) can present with several different phenotypes: polymyositis (PM), dermatomyositis (DM), systemic sclerosis (SSc), scleromyositis, or sclero-dermatomyositis. Pulmonary arterial hypertension…
Abstract Number: 221 • 2012 ACR/ARHP Annual Meeting
Expanding the Clinical and Serological Spectrum of MDA5-Associated Dermatomyositis
John C. Hall¹, Livia Casciola Rosen¹, Sonye K. Danoff², Lesly-Anne Samedy³ and Lisa Christopher-Stine⁴, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Medicine and Neurology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is a heterogeneous systemic disease with specific autoantibodies (Abs) which correlate with unique clinical phenotypes. Melanoma differentiation-associated gene 5 (MDA5) Abs have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].